The Optispan Podcast with Matt Kaeberlein

The Galleri multi-cancer detection test made headlines when its landmark NHS trial failed to meet its primary endpoint, sending Grail's stock down nearly 50%. But does that mean Galleri is useless? Not exactly.
In this episode, Dr. Matt Kaeberlein breaks down what the NHS Galleri trial actually measured, why missing a primary endpoint doesn't tell the whole story, and what the results mean for three distinct groups: the general population, high-risk individuals, and people considering the test for themselves.Timestamps:0:00 — What is Galleri? Multi-cancer detection explained0:44 — Would Dr. Kaeberlein take the test? ($1,000 question)1:29 — Episode overview: defense, takedown, or something else?2:30 — How Galleri works: circulating tumor DNA and methylation3:23 — The core promise: early detection across 50+ cancer types4:20 — The NHS Galleri trial: 140,000 participants, 3 years5:15 — Trial results, the press release spin, and the stock drop5:59 — How OptiSpan currently uses Galleri in practice6:43 — Pre-trial take: not ready for population screening, but why?7:32 — The real risks: false positives, false negatives, and downstream consequences9:05 — What it takes to justify population-level screening10:48 — Inside the NHS trial design12:40 — Why the trial was set up to be difficult from the start13:29 — What the positive signals in the data actually suggest15:49 — High-risk individuals: does Galleri make sense for them?17:38 — Individual-level decision-making: what you need to consider18:33 — Sensitivity and specificity explained plainly22:07 — Walking through the math: false positives in the real world24:20 — Retesting after a positive signal: an open question25:00 — Sensitivity by cancer stage and aggressiveness25:45 — Final verdict: does Galleri have clinical value?27:25 — Dr. Kaeberlein's personal decision on taking the test

What if menopause is one of the most important longevity events in human biology, and we've been ignoring it?

Dr. Matt Kaeberlein sits down with Dr. Jennifer Pearlman, founder of PearlMD and pioneer in female-centric longevity medicine, to unpack why women's health has been systemically underfunded, undertreated, and misunderstood and what a proactive approach actually looks like.

From the flawed science behind the Women's Health Initiative to the nuts and bolts of hormone optimization, testosterone for women, and the emerging field of ovarian tissue cryopreservation, Dr. Pearlman brings 20+ years of clinical expertise and a framework she calls FemSpan: harnessing the unique biology of female longevity while mitigating the risks most medicine ignores.

Timestamps:
00:00 — Cold open
00:47 — Welcome & Dr. Pearlman's origin story
02:33 — Why the medical system fails women
08:37 — How the women's health landscape has shifted over 20 years
09:26 — The Women's Health Initiative: what went wrong
13:07 — What drove the reemergence of menopause medicine
14:38 — Big Pharma, funding, and the micronized progesterone question
17:13 — "Medicine progresses one funeral at a time"
18:01 — From functional medicine to precision medicine
20:35 — Rebranding aging: from anti-aging to longevity
23:50 — Navigating the gray zone between frontier and fringe
27:46 — How to identify credible practitioners
33:32 — What every woman should know about the menopause transition
36:41 — Why take a proactive approach? Symptoms, disease risk, and aging
38:19 — The two simultaneous biology processes of menopause
41:46 — The role of FSH and hormone optimization
43:28 — Estradiol as the body's regenerative signal
47:24 — What to test and when
50:38 — The metabolic theory of menopause
55:08 — Visceral fat as an evolutionary adaptation
57:26 — How to navigate hormone therapy
01:00:24 — Bioidentical hormones: reclaiming the term
01:06:45 — Why route of administration matters
01:11:35 — Progesterone: the unsung hero of menopause management
01:23:19 — Testosterone for women: what the science actually says
01:34:25 — Introducing FemSpan: the female longevity framework
01:37:55 — The biological aging advantages women carry
01:46:46 — Can we close the healthspan gap?
01:53:05 — Could reversing menopause extend female lifespan?
02:00:29 — Regenerative medicine and the future of female longevity
02:03:10 — Ovarian tissue cryopreservation explained
02:10:39 — AI in women's precision medicine
02:15:50 — Medicine at scale: opportunity and risk
02:21:41 — Advanced cardiovascular diagnostics and the female gap
02:24:22 — Closing thoughts: your aging trajectory is more in your control than you think

Dr. Kim Brockenbrough: https://www.cardiavision.com/https://www.linkedin.com/in/kimberly-brockenbrough-md-1b321a123/https://www.instagram.com/kimbromd?ighsh=YjVpcDcwdHA3ejVvYour calcium score came back zero. You're in the clear, right? Not so fast.In this episode, Optispan Clinical Director Dr. Nicki Byrne sits down with Dr. Kim Brockenbrough, board-certified cardiovascular radiologist, 25-year veteran of vascular imaging, and CEO of CardiaVision, for a conversation that challenges one of the most common assumptions in preventive cardiology.If you care about cardiovascular longevity, and you should, because heart disease remains the leading killer, this is the imaging conversation you didn't know you needed.Timestamps:00:00 — Cold open: The 48-year-old runner with an 80% blockage and a zero calcium score00:54 — Dr. Nicki Byrne introduces Dr. Kim Brockenbrough & CardiaVision01:45 — Dr. Brockenbrough's background: 25 years of vascular imaging02:35 — Cardiovascular disease through a longevity lens: imaging vs. labs vs. functional testing03:24 — The lifecycle of plaque: from fatty deposits to rupture and heart attack04:21 — Why soft plaque is more dangerous than calcified plaque (SCOT-HEART 2020)05:14 — How calcium scores are used in clinical practice — and where they fall short06:18 — The only way to see soft plaque non-invasively: coronary CT angiography (CCTA)07:08 — Which populations are most at risk of a false sense of security from calcium scoring08:03 — What a CCTA can tell you that a calcium score can't09:43 — How often should patients follow up with repeat scans?10:28 — Higher vs. lower dose radiation protocols — and why Dr. Brockenbrough chooses higher dose11:17 — Risks of CCTA: contrast reactions, kidney considerations12:15 — Stress tests vs. CCTA: why a negative stress test is a very low bar13:21 — Soft plaque that isn't flow-limiting: small emboli, dementia, and congestive heart failure15:36 — Medications that reverse plaque: statins, PCSK9 inhibitors, and the LOCATE trial16:23 — LDL reduction and plaque regression: what the data shows17:08 — High-intensity statins vs. Repatha — tolerability, efficacy, and the price drop18:27 — When OptiSpan reaches for PCSK9 inhibitors: ApoB, LDL, Lp(a), ApoE4, and significant disease19:22 — Why a rising calcium score on a statin is exactly what you want to see20:25 — AI plaque quantification tools: promise, limitations, and validation concerns22:54 — Has AI ever changed Dr. Brockenbrough's read? A real-world case23:40 — FFR-CT, the ISCHEMIA trial, and why stenting asymptomatic patients is no longer standard of care25:25 — The future of cardiac imaging and the case for universal CCTA screening26:52 — The patient experience: what to expect at a CardiaVision CCTA appointment28:18 — Why seeing soft plaque changes patient behavior — the power of treating disease, not numbers29:49 — Bridging the gap between longevity medicine and traditional cardiology33:11 — Testosterone, the TRAVERSE trial, and what you should know about your coronaries first35:41 — What causes coronary artery disease beyond cholesterol: sugar, inflammation, gum disease37:07 — Image walkthrough: soft plaque vs. calcified plaque on a real CCTA41:36 — Where to find Dr. Brockenbrough and CardiaVision

Links to All Articles Mentioned:
https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-riskshttps://www.fda.gov/media/174456/downloadRFK Jr. just appeared on the Joe Rogan podcast and peptides were front and center. Dr. Matt Kaeberlein breaks down the conversation in real time, fact-checking claims about peptide efficacy, FDA regulation, and the growing black market for compounded peptides.What does the science actually say? What did RFK get right and where did the conversation miss the mark? Dr. Kaeberlein cuts through the noise with a scientist's lens, covering everything from BPC-157 to GLP-1 agonists to the FDA's Category 2 bulk drug substances list.If you're navigating the peptide space and want clarity over hype, this one's for you.Timestamps:00:00 — Intro & Episode Overview01:06 — RFK on Joe Rogan: The Peptide Conversation Begins02:06 — First Fact Check: "We Know Peptides Work"03:50 — GLP-1 Agonists: The Exception, Not the Rule05:05 — RFK's Personal Peptide Experience06:32 — The FDA's Bulk Drug Substances List Explained08:32 — FDA Category 2: What It Actually Means09:21 — The Peptides That Were Banned From Compounding10:18 — Did the FDA Consider Safety? Here's What the Data Says12:03 — Real Cases of People Harmed by Compounded Peptides13:40 — Can the FDA Consider Efficacy? Reading Directly From the Guidelines15:44 — The Peptide Black Market: How It Emerged17:54 — Will Reversing the Ban Actually Fix the Problem?19:20 — RFK's Push to Move 14 Peptides Back to the Bulk List20:16 — Dr. Kaeberlein's Take: Informed Patient Access Matters21:51 — Who Created the Black Market?22:46 — What Would Actually Help: Funding Real Clinical Trials23:36 — Final Thoughts & Call to Action

What does over 18 months of precision medicine actually look like in practice? In this episode of the Optispan Success Story Series, Dr. Matt Kaeberlein sits down with Carlos Pinto, a tech executive and early Optispan client, to trace his longitudinal health journey from metabolic warning signs to measurable, sustained transformation. Carlos shares how a decade of overlooked biomarkers, a post-pandemic health decline, and a single panic attack became the catalyst for a data-driven approach to his own biology. Together, he and Dr. Kaeberlein review real DEXA, lipid, metabolic, and environmental biomarker data, unpacking what moved the needle, what didn't, and why the answer was rarely simple. This conversation is a candid look at what it means to become your own best health advocate, not through quick fixes, but through personalized, longitudinal learning.Timestamps:0:00 – Cold open & highlights0:50 – Welcome & Carlos's background in tech leadership2:15 – How career ambition displaced health in his 20s and 30s3:39 – A panic attack as the turning point: connecting mental and physical health4:24 – A previous medical wellness program: what worked and what was missing6:34 – Arriving at OptiSpan: intention, mindset, and expectations7:15 – Gateway Day: comprehensive baseline testing and initial surprises8:51 – Early metabolic lessons: CGM data, glucose spikes, and dawn effect11:32 – Confronting white coat hypertension with 78 data points13:28 – How stress, sleep, and nutrition interact to drive metabolic dysfunction15:44 – Personal experimentation as methodology: berberine, time-restricted eating, and fish17:09 – Mercury toxicity from fish consumption: a case study in biomarker surveillance18:33 – Stress management protocols: walking, meditation, and measurable outcomes19:49 – Statin introduction: the role of medication as a tool, not a failure20:27 – DEXA results: visceral fat reduction, body fat loss, and lean mass gain24:17 – Lipid profile transformation: ApoB from ~115 to 70, LDL from 160 to 7425:57 – A1C trajectory and the complexity of glucose optimization30:01 – Reframing medication: proactive use vs. reactive disease management31:29 – Mercury biomarker deep dive: from 2.4 to 16 and back to 232:21 – Goals for the future: sustainability, muscle retention, and mental clarity36:30 – Lineage biological age algorithm: from mortality risk of 54 to 5239:27 – Closing reflections: health as a lifelong trajectory, not a program